|
AU4273297A
|
|
Topical composition containing hyaluronic acid and NSAIDS
|
|
AU7022496A
|
|
Use of hyaluronic acid and forms to prevent arterial restenosis
|
|
CA2122551A1
|
|
Clearing of atherosclerosis
|
|
CA2122519A1
|
|
Cancer treatment and metastasis prevention
|
|
CA2121454A1
|
|
Inhibition, control and regression of angiogenesis
|
|
CA2120045A1
|
|
Use of Hyaluronic Acid and Forms to Prevent Arterial Restenosis
|
|
CA2106695A1
|
|
Hyaluronic Acid and Forms to Prevent Arterial Restenosis
|
|
WO9407505A1
|
|
Use of hyaluronic acid and forms to prevent arterial restenosis
|
|
CA2097892A1
|
|
Prevention and control of cancer
|
|
CA2094203A1
|
|
Inhibition of angiogenesis
|
|
IL104796D0
|
|
Formulations containing hyaluronic acid
|
|
CA2089635A1
|
|
Treatment of disease employing hyaluronic acid and nsaids
|
|
CA2089621A1
|
|
Formulations containing hyaluronic acid
|
|
CA2061566A1
|
|
Treatment of disease employing hyaluronic acid and nsaids
|
|
CA2061703A1
|
|
Formulations containing hyaluronic acid
|
|
EG20171A
|
|
Treatment of conditions and disease
|
